AKA: Marsilid, Rivivol, Euphozid, Iprazid, Ipronid, Ipronin
Iproniazid is a non-selective, irreversible, monoamine oxidase inhibitor #maoi.
Iproniazid initially caught my attention due to its distant similarity to #cathinone. Surprisingly, the most interesting aspect of iproniazid is its history as opposed to its pharmacology.
The year was 1951; Isomiazid and Iproniazid, two hydrazide derivatives, were introduced for the treatment of tuberculosis by Roche, Squibb, and Lily. Soon after Iproniazid's introduction, Nathan Kline discovers its #antidepressant effects. Jack Saunders, a former employee of Ciba, then joins Kline at Rockland State Hospital of #NewYork in 1956 to study the #psychotropic effects of Iproniazid. In 1957 Kline believed the drugs antidepressant effects were significant and approached the managing director of Roche, David Barney. However, Barney showed little interest in the Iproniazid. Later in the year Kline went on to present the "Psychic Energizing" effects of Iproniazid at the American Psychiatric Association's regional meeting in #Syracuse, New York. This presentation was reported by the #NewYorkTimes and soon after Iproniazid was being used for "anti nervousness properties." This discovery earned Kline the Lasker Award, and he was invited to write and article on Iproniazid in the Journal of American Medical Association. Later on Kline's former partner Saunders sued for a portion of the Lasker prize. There were several hearings prior to Kline's death in 1981. However, it has been said that previous research of Max Lurie trumps both Kline's and Saunders'. Source: History of Psychiatry and Medical Psychology